Tag Archives: Tuberculosis

TB and Undernutrition: A Vicious Circle

Tuberculosis (TB) and Undernutrition are two of our key issues at Results. Both have a devastating impact on the lives of the poor in developing countries, yet both have a worryingly low profile in the aid and development discourse in donor countries. They are also two issues that are closely intertwined.

Credit: UNITAID

Credit: UNITAID

It has long been known that there is an association between TB and malnutrition, although it is difficult to determine what the nutritional status of individuals with TB was before the onset of the disease. Malnutrition makes people more susceptible to the development of active TB, and  active TB contributes to the development of malnutrition. This vicious circle impacts not only on individuals but can easily transfer to their families and their communities.

Tuberculosis patients have lower Body Mass Index (BMI), muscle mass and subcutaneous stores of fat than control groups. A study in Malawi found that the differences can amount to as much as 20% between healthy individuals and those with active TB. This may be because some participants in the study suffered malnutrition before contracting TB, but the disease also increases demand for energy which contribute to increased weight loss if that demand cannot be met.

In full treatment, TB patients can quickly recover the weight that they have lost, but researchers have consistently found that muscle-mass and protein levels are much slower to recover. Even in patients deemed to be ‘cured’ of TB, these nutrient deficiencies can persist. This is one reason that comprehensive care for TB patients is vital long after the body has been cleared of bacteria.

There is also evidence to suggest that malnutrition, and the consequential weakness in immune function, makes it more likely that exposure to TB bacteria will result in full tuberculosis, rather than development of the latent form of the disease that is found in 2 billion people around the world. Therefore, improvements in nutrition for people who are most at risk of developing TB  should directly decrease the number of TB infections, improve treatment prognoses and save lives.

On 8th June the UK and CIFF will host a global summit called Nutrition for Growth to raise attention, and funding for long-term nutrition programmes, prioritising at first 20 countries that have a high-burden of undernutrition. RESULTS is calling on the UK to make a pledge of £150million a year, or £750million over five years. A multi-year pledge is important to give stability to developing countries and allow for long-term planning and scaling up of nutrition-specific programming within stronger health systems. An improved global investment in nutrition will not only lead to a reduction in child deaths but will have an important long-term impact in reducing diseases as adults.

Good nutrition won’t definitely stop you getting tuberculosis, but it certainly gives you a better chance of fighting it successfully. If the world truly wants to see a reduction in the burden of global diseases like TB, ensuring good nutrition for all would be an excellent first step.

Note: For a more comprehensive review of evidence linking TB and undernutrition, click here

Urgent News on Mr Mkoko from ‘They Go To Die’

Yesterday, Jonathan Smith, epidemiologist and director of ‘They Go To Die’, received news that the only surviving miner in the film-Mr Mkoko-has been hospitalised with tuberculosis again.To find out more about Mr Mkoko’s condition and what you can do to help, have a read of this personal message from Jonathan Smith and share with your networks. Our thoughts and messages of support go out to Mr Mkoko and his family during this difficult time.

This week I received a call from Nozipho Mkoko (Musa Mkoko’s wife) informing me that Mr. Mkoko has been hospitalised with tuberculosis. Today, the Mkoko family granted me permission to share this news with you all. As many of you know, Mr. Mkoko is the only surviving miner from the film, They Go to Die. His recent TB infection is an externally acquired infection, not a reinfection of his previous multi-drug resistant TB.  At the end of this message I have listed direct ways to help, as well as how to access an unpublished link to a clip of Mr. Mkoko from the film. I invite you to watch.

Credit: Jonathan Smith

Credit: Jonathan Smith

This news is extremely worrisome, and though the facts that he is receiving care in Swaziland and that his TB is treatable mitigates some of the worry, we must also remember that there are intense mental and psychological effects of such a diagnosis. Though the treatment for drug susceptible TB is less intense, it is by no means considered a simple treatment; one’s family would not be ‘relieved’ that they were diagnosed with a different form of cancer. As you can imagine, this news has been mentally and emotionally devastating to not only him, but also his family and community.

It is easy to assume that ‘care’ equals ‘cure.’ We are fortunate that the Swaziland Health Minister Benedict Xaba has greatly improved care and that access to medication is no longer a hurdle. But given his physical state – weak, emaciated – and that his TB is complicated by HIV, a favourable outcome is neither guaranteed nor probable. This all too seriously highlights the continued battle that high-risk individuals have for contracting TB. Mr. Mkoko’s family will fight tooth and nail to ensure his well-being, just as they did during his last battle, and just as they would if they faced one hundred battles more, but he is weaker, older, and his lungs are lacerated from spending decades in the dusty mineshafts where he once worked.

If you are like me, you empathize with Mr. Mkoko and have the urge to want to ‘do something.’ But we should remember our version of the TB epidemic is not the same as Mr. Mkokos, however our epidemic is equally as challenging. As the family of Mr. Mkoko fights their own battles, we must realize that our fight is not in the dim lit homes of a Swazi house. Our role is not to change the wet sheets of a shivering father who has perspired through them, or in navigating public transport for a full day to secure a blister pack of pills. Our fight is to ensure that those fighting these battles have the tools they need to win; that the Global Fund is funded, that the research and innovation we need comes to fruition, that TB REACH is expanded, that the mines lower risk, and that data-driven policies that support patient centered care are rolled out. In continuing to fight the battles we face in our epidemic, we can ensure that future patients avoid illness and physical and mental distress. Though being behind a lab bench or keyboard can often times seem distant, it is equally as important as being in the field.

The TB epidemic will not be overcome in a single broad, sweeping gesture – rather success will manifest itself in sustaining the countless individual efforts fought daily around the globe. It is up to us to define our own fight.

I ask that you keep Mr. Mkoko in your thoughts and prayers. He is one case out of the 8.7 million cases of TB in the world at present, but he represents the positive side of fighting an epidemic – that people can overcome incredible obstacles. He and his family are a representation of why we all fight to overcome TB.

If you would like to help the Mkoko family, you can do so in the following ways:

1) Email the family a message of hope and compassion. We have set up Mrs. Mkoko with a Gmail account that she can check periodically. Click here to email the Mkoko Family.

2) Donate to directly support Mr. Mkoko’s care. We have created a special fund for the Mkoko Family. We are not soliciting funds per se, but this is indeed a tangible way we can help; sometimes defining our fight is as simple as sustaining the efforts of others. Click here to donate

3) If you haven’t yet done so, download our letter and email your MP demanding that the UK fully fund the Global Fund to Fight AIDS, TB and Malaria and TB REACH. You can find your MP’s details at www.theyworkforyou.com

4) To access the clip, click here and use the password ‘mkoko.’ I will leave this up for about two weeks.

Onward,

Jonathan Smith

Guest Blog: A Call For History Makers

Todays guest blog post is brought to you by Endalkachew Demmiss, author of ‘The Mystery of God’s will’.

In 2004, I was a bed-ridden multidrug-resistant tuberculosis (MDR-TB) patient and missed class for more than two years. Before 2008, the medications were not available in Ethiopia. During those days, patients like myself were isolated in small rooms, waiting for their death due to the lack of access to expensive of anti-tuberculosis drugs. That was my fate. Fortunately I was able to get the life-saving drugs miraculously from a charitable organization, like the programs now supported by the Global Fund to Fight AIDS, Tuberculosis and Malaria. After two years of suffering from the drug’s side effects I got the opportunity to go back to school and pursue my career as a pharmacist and global health advocate.

Credit: Claire Moodie

Credit: Claire Moodie

Our world can be a safe place to her inhabitants, but only if we win the fight against epidemics, which have showed time and again throughout history to be one of the greatest threats to our global brothers and sisters. Epidemics like the black plague, smallpox, measles and today, AIDS, TB and malaria have dealt devastating impacts for human kind.

Can you imagine if there weren’t scientists, committed political leaders or health professionals standing in the gap during these challenging times? My existence would have been threatened without these heroes. They have given us tools through modern science, political will and effective partnerships like the Global Fund, to make staggering advances in global health in the short space of just over a decade.

In developing countries, HIV/AIDS, TB, and malaria continue to kill at an alarming rate, more effectively than war. These major global health threats cause substantial morbidity, mortality, negative socioeconomic impact, and human suffering. Disease-specific interventions have had a considerable impact on improving health systems. However, we still need more resources, more research and attention from the global community to get tangible results on prevention, treatment and patient care. It’s time for the Big Push to defeat these diseases and we need champions and heroes now more than ever.

During the time of my fight against MDR-TB, we faced dramatic challenges, but now because of the effective interventions financed by the Global Fund and its partners, people can have a chance to get the medications freely. The Global Fund stands between life and death of millions and needs donors’ commitment for increased and sustained funding.

This is my call — from a poor nation to history makers — to be the generation who can change the course of history. Let’s march mercilessly against TB, HIV and malaria. In an age of vaccines, antibiotics and dramatic scientific progress, these diseases can be brought under control.

This post is part of a series produced by The Huffington Post, The Global Fund, and its partners as part of The Big Push campaign. For more information on The Global Fund, click here. To read more posts about The Big Push — The Global Fund and its partners efforts to eradicate HIV/AIDS, malaria and tuberculosis — click here.

Dying For Gold tour updates from Warwick, Birmingham, Glasgow and Southampton

In the last 5 days we have ventured to the Midlands for screenings in Warwick and Birmingham, back to Scotland for the Medcin Global Health Conference and then back down to the South of England for a screening in Southampton last night! Tonight we are in Bristol,tommorrow in Poole, then back to London for the screening at the Ritzy Cinema on Wednesday night and the LSHTM event on the Friday evening.

Have a read below to see what we have been up to and remember to sign the petition, calling on Anglo Gold Ashanti to PREVENT, FIND and TREAT TB in their minees, if you havnt already.

Day 7: Warwick

We spent the majority of the morning working away in the dining room of our cozy Cambridge lodge. After lunch we headed for the university bubble of Warwick where we teamed up with student hub’s members Jo and Harshil. Whilst Saoirse and the student hub’s team flyered for the evening’s screenings Felix and Jonathan set up camp in the library cafe to work on their respective presentations for Medsin’s Global Health Conference on Thursday.

As it was the last day of term the evening’s screening was an intimate affair but the audience were engaged and asked lots of interesting questions. We discussed the BCG vaccine- its ineffectiveness in treating TB of the lungs and the progress in developing new vaccines. We also talked about the economic case for the mining companies to implement best practices for dealing with TB in the mines. The World Bank are currently doing a cost-benefit analysis of this situation and have estimated that the mining industry is losing out on around $783 million dollars in terms of treatment for miners who have contracted silicosis and TB; training up new workers to replace those who have become too ill to work; and the money lost in wages to those retrenched miners.

Staying in Birmingham tonight with Felix’s old chum.

Continue reading

What is the UK’s role in the response to rising rates of drug-resistant TB?

On Wednesday 13th February, parliamentarians from the APPG on Global Tuberculosis held an oral evidence session with key Global TB experts as part of its inquiry into drug-resistant TB (DR-TB). Parliamentarians including Andrew George MP (Chair of the session), Nick Herbert MP, Baroness Masham of Ilton, Virendra Sharma MP, Cathy Jamieson MP, Annette Brooke MP and Michael Connarty MP heard from the following witnesses:

  • Dr Lucica Ditiu, Executive Secretary, Stop TB Partnership, World Health Organisation;
  • Dr Aamir Khan, Executive Director, The Indus Hospital, Pakistan;
  • Jason Lane, Senior Health Adviser (TB), Department for International Development (DFID);

Parliamentarians questioned the panellists on the scale of the problem and the threat that it poses here and abroad; costs of medicines; length of treatment; access to medicines; what steps the UK, through DFID, is taking to help tackling growing rates of the more complex form of the disease in developing countries; the importance of R&D into new tools to tackle TB; and support from the UK for the Global Fund to fight AIDS, Tuberculosis and Malaria, which accounts for over 82% of international financing towards TB.

Aim of the inquiry

The APPG is producing a short report building on the Parliamentary Office of Science Technology Note on drug-resistant TB (pdf) published in July 2012. POST is Parliament’s in-house source of independent, balanced and accessible analysis of public policy issues related to science and technology. The note examines the extent of, and risks posed by, drug-resistant TB as well as an overview of UK and international TB surveillance, research into treatments and policy options to limit infections.

It is not the role of POST to provide recommendations in reports that it publishes. It is for this reason that the APPG is seeking views on the current challenges of DR-TB in the UK and in developing countries – as defined in the 4 page note – with specific attention paid to the current and future response of the UK Government.

The final report will be submitted to the Departments for International Development (DFID) and Health (DH) and used to inform the APPG’s work in this area going forward.

Information on written and oral evidence

The initial ‘written call for evidence’ phase of the APPG on Global TB’s inquiry into drug-resistant TB (DR TB) concluded in September 2012. The group received over 30 responses from CSO’s, multilateral organisations, Academics and key TB experts.

The second ‘oral evidence’ phase of the inquiry involved four ‘hearings’ – two focusing on the UK and two on the global burden of DR-TB – where members of the group explored in more detail some of the issues emerging from the written evidence and POST note.

Report publication

The final report is due to be launched ahead of World TB Day (24th March), and a meeting with the Parliamentary Under Secretary of State for International Development, Lynne Featherstone MP, is being scheduled to discuss the findings and recommendations.

If you want to know more about the work of the All-Party Parliamentary Group on Global Tuberculosis, visit www.appg-tb.org.uk.

Ex-miners seek silicosis class action against gold mining companies

A South African lawyer has filed for a class action lawsuit against 30 gold mining companies whose ex-workers claim to have contracted silicosis, a debilitating lung disease caused by health and safety negligence.

Credit: Tilt

Attorney Richard Spoor has already signed up 17,000 plaintiffs and around 500 new individuals are joining the battle for compensation each month. The planned suit has its roots in last year’s landmark ruling by the Constitutional Court which announced that for the first time lung-diseased miners would be able to sue their employers.

Silicosis is contracted through the constant inhalation of silica dust released during controlled explosions in mines or whilst using pneumatic drills. Inadequate dust disseminating technology and health and safety precautions on behalf of the mining companies have led to an estimated 1 in 3 miners contracting silicosis. The disease severely damages the lungs causing chest pains, cough and fever and predisposes the individual to developing Tuberculosis as a secondary disease. Some mining companies offer basic health facilities for miners but these do not extend into the miner’s communities once they become too ill to work and are sent home. With no known cure, ex-miners with silicosis are unable to work to support their families and often become isolated within their communities.

“When mine owners skimp on the cost of providing proper ventilation, workers get sick. These men have become ill through no fault of their own, yet, when they do, they are simply dismissed, and they and their families are left to languish in poverty and disease.” Said Spoor in a recent press release. “We seek no more than the application of the ‘polluter pays’ principle to be applied to an industry that generates sick men as surely as it produces great wealth for its shareholders.”

Spoor expects the hearing to be held in either April or May this year. Meanwhile a similar lawsuit has been filed by UK legal firm Leigh Day & Co. against another South African gold mining company Anglo American. The mining company is disputing the jurisdiction but Lawyer Richard Meeran has stated that the company’s negligence is ‘a flagrant disregard for the health of its back workers’ and continues to fight against this injustice.

US approves treatment for multidrug-resistant tuberculosis

Yesterday, the US Food and Drug administration (FDA) approved a new drug for multidrug-resistant tuberculosis that can be used as an alternative treatment when other drugs fail. The drug, to be called Sirturo, was developed by Janssen Therapeutics, the pharmaceuticals unit of Johnson & Johnson, and is the first in a new class of drugs that aims to treat the drug-resistant strain of the disease. Sirturo, also known as bedaquiline, will be used on top of standard treatments and works by blocking an enzyme the disease pathogen needs to spread throughout the body.

Even as it announced the approval, however, the FDA has cautioned that the medication may lead to a risk of heart problems and has advised doctors to prescribe the treatment carefully.

“Multidrug-resistant tuberculosis poses a serious health threat throughout the world, and Sirturo provides much-needed treatment for patients who have don’t have other therapeutic options available,” Edward Cox, director of the office of antimicrobial products in the F.D.A.’s centre for drug evaluation and research, said in a statement. “However, because the drug also carries some significant risks, doctors should make sure they use it appropriately and only in patients who don’t have other treatment options.”

Of the nine-million active cases of TB in the world, about half a million are caused by multi-drug resistant tuberculosis, which manifests when the disease pathogen Mycobacterium tuberculosis becomes resistant to isonazid and rifampin, the two drugs most widely used to treat TB. Although there were only 100 cases of multidrug-resistant TB in America last year, elsewhere the disease is a growing problem, especially in regions of Africa, South Asia and Eastern Europe. The approval of this new treatment for MDR TB marks an important development in the fight against TB and this strain of the disease, however careful monitoring of its success and side effects will be important, before the drug is rolled out on a larger scale.

UNITAID approve new grants worth US $120 million

Last week I attended the UNITAID bi-annual board meeting in Geneva. As the snow fell around us, board members from key donor countries, foundations, NGOs and affected communities discussed the merits of 20 new project proposals.

UNITAID is an innovative funding mechanism set up in 2006, working to fill a critical gap in global health financing. It provides a sustained and strategic market intervention that aims both to decrease the price of medicines for priority diseases and to increase the supply of drugs and diagnostics for HIV/AIDS, tuberculosis and malaria. The new grants will allow hundreds of thousands of children in developing countries to access better and more affordable medicines for these three diseases and help save thousands of lives a year in low-income countries.

I was especially pleased to see a focus in this round of grants on paediatric treatments. There are few child-adapted treatments available globally and the small markets mean some pharmaceutical companies have not invested in new products because the profit element is uncertain. The civil society delegations felt strongly that these diseases need to have a higher profile on the global agenda, and the board agreed.  “For too long now, the global health community has done too little to meet the special needs of children living with these diseases in poor countries,” said Dr Philippe Douste-Blazy, Chairman of the UNITAID Board. “With very few child-adapted treatments available, both paediatric HIV and tuberculosis have been at risk of becoming neglected diseases”. Now the new UNITAID investment will allow the production of adapted treatments.

UNITAID is an interesting global body because most of the available funds are raised through innovative funding sources such as a small tax on air tickets. DFID, the British Department for International Development, is an important donor to UNITAID and gives funds through their standard aid budget. The UK and France between them provide around 80% of UNITAID funds. Sadly some countries, such as Spain, who were significant donors, have cut their contribution completely due to the economic downturn in Europe.

During the meeting, it came to light that an exciting US$ 16 million approved grant to the TB Alliance to support the production of appropriate paediatric TB medicine formulations. Currently, a lack of child-adapted TB medicines contributes to high morbidity among children. More details of the approved grants will be on the UNITAID website.

The last item on the Board agenda was to discuss 8 proposed ‘market entry grants’. This is the first time grants of this sort have been considered and approved. Four grants were conditionally approved (pending due diligence process). These would help manufacturers of “point-of-care” HIV diagnostic machines in the final stages of development get over the hurdles of  making their products available to those in need.   “These investments follow a rigorous year-long process of in-depth market intelligence led by the UNITAID Secretariat, which analysed the market for treatments and diagnostics to inform the current round of grant-making decisions,” added Dr Douste-Blazy.  This work will soon be translated into lives saved through the provision of better health products that these projects will ensure.”

RESULTS UK, and other civil society organisations will be following the development of these new projects closely in 2013. RESULTS colleagues in Japan, Australia and the USA have the long term hope that these countries will become donors to UNITAID in the near future.

RESULTS welcomes Steve Lewis to the team

We are very pleased at RESULTS UK to welcome a new staff member, Steve Lewis, who will lead the global health advocacy team. We asked Steve to tell us a little about himself…..

Hi All,

I’m excited to be joining RESULTS now, at such an important time. RESULTS is growing and moving to new offices, and there is a huge amount of work to be done on issues such as the EC aid budget, the UK moving slowly towards the 0.7% aid target, and still poor  progress on new vaccines that are urgently needed for an improved response to tuberculosis.

In my career I have worked in Ecuador, El Salvador and Zimbabwe, and worked on some inspiring health projects. In El Salvador I worked for three years with community health workers, walking from village to village in beautiful countryside, carrying out vaccination campaigns and raising  awareness of basic health messages. In Zimbabwe in the 1990s all the organisations I worked with were being devastated by the HIV/AIDS pandemic, which led me into work with the International HIV/AIDS Alliance. I worked at the Alliance for six years and was able to see the amazing response to HIV that can be achieved with the participation of community groups and ‘key population’ activists. For example, I am proud that during my time at the Alliance we agreed to give the first support and funding to the fledgling Latin America Network of Sex Workers, and now a few years later they are implementing their own major GFATM funded project across the whole region.

For the last five years I have been working as Head of Advocacy at VSO International, where alongside work on education and HIV/AIDS we carried out research and lobbying on health system strengthening. VSO volunteers around the world noted with alarm the shortage of health workers in most of the poorest countries in the South, and we tried to raise awareness of this situation with major institutions and worked to suggest innovative solutions. Some of these revolved around Community Health Workers and Home-based Care, which I know is an area of importance to RESULTS as well.

I look forward to working with the team here, and I know that our work in the office is immensely strengthened by the campaigning and advocacy done by grassroots RESULTS groups and supporters around the world.

Steve Lewis

RESULTS welcomes Mark Dybul as the new Executive Director of the Global Fund to fight Aids, Tuberculosis and Malaria

Last Thursday, Dr Mark Dybul was selected to serve as the next Executive Director of the Global Fund to Fight AIDS, Tuberculosis and Malaria. The appointment marks the start of an exciting new chapter for the world’s largest health financier as the organisation initiates organisational changes that will significantly alter the way the organisation is run.

Credit:International Aids Society

Dr. Dybul is widely recognised as a visionary leader on global health for his role in helping create and then lead the President’s Emergency Program for AIDS Relief, known as PEPFAR, which has been highly effective in helping limit and reverse the growth of HIV infection worldwide.  Currently, Dybul co-directs the Global Health Law Program at the O’Neill Institute for National and Global Health Law at Georgetown University.

After 10 years of delivering health services to those most in need, last year Global Fund management initiated organisational changes to improve the way the fund invests in health programmes and ensure  that resources are directed into the country’s that have been hit-hardest by AIDS, tuberculosis and malaria. Mark Dybul joins the organization as it completes these improvements, evolving from an emergency response mechanism to a more sustainable funder of health.

Specifically, the Global Fund is now focusing greater attention on the people it serves. For example, the Global Fund management decision to restructure staff has increased personnel and attention on the organisations core work-grant management-especially in its 20 highest-impact countries. This is already translating into success on the ground. In Zambia, for example, the Global Fund recently doubled the size of its grant staff and strengthened its country team, including procurement, finance, monitoring and evaluation, and legal experts.

Additionally, the Global Fund Board has recently approved a revamped funding model for its future grants. The new model is designed to significantly improve the way the Global Fund invests in health programs, simplifies the application process and better target resources to those most who are most in need. As the Global Fund and Dr Dybul move toward implementing this new funding model, resources should flow more efficiently to support lifesaving programs.

RESULTS looks forward to working with Mark and his team as we continue our shared mission of improving the health of millions of people across the world. Welcome Mark!